Janpix

About:

Janpix operates as an oncology-focused startup.

Top Investors: Medicxi

Description:

Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been very challenging thus far and Janpix developed new chemistry to address this complex problem.

Total Funding Amount:

$27.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2013-01-01

Founders:

Patrick T. Gunning, Pierre Cortes

Number of Employees:

1-10

Last Funding Date:

2020-10-07

IPO Status:

Private

Industries: